Physician profile
Rodney Collins
NPI 1700879061
$36,574.73
in general payments reported to CMS, 2019-2025
53 companies · $7,620 in 2025
The $7,620 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,839 · 2020: $2,791 · 2021: $5,249 · 2022: $3,716 · 2023: $5,194 · 2024: $8,166 · 2025: $7,620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21K · Education: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20,837.00 |
| Education | $142.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,142.14 | 2019-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $4,700.87 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Lundbeck LLC | $2,393.59 | 2019-2025 | Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $2,225.16 | 2019-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,204.05 | 2020-2025 | Caplyta |
| Alkermes, INC. | $2,138.42 | 2019-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $2,121.10 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $1,805.91 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $1,638.57 | 2022-2025 | Auvelity, Sunosi |
| Teva Pharmaceuticals USA, INC. | $1,401.11 | 2020-2025 | Uzedy, Austedo Xr |
| Viiv Healthcare Company | $1,234.68 | 2019-2025 | Apretude, Dovato, Cabenuva |
| Allergan, INC. | $988.78 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $974.53 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $936.59 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $755.68 | 2019-2025 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $691.39 | 2019-2025 | Sublocade |
| Almatica Pharma LLC | $636.92 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $633.25 | 2019-2025 | Xifaxan, Relistor |
| Idorsia Pharmaceuticals US INC | $529.06 | 2022-2024 | Quviviq |
| Supernus Pharmaceuticals, INC. | $360.22 | 2022-2025 | Qelbree, Qelbree |
| Theratechnologies INC. | $301.00 | 2019-2024 | Trogarzo, Egrifta |
| Luye Pharma (USA) LTD. | $270.62 | 2025 | Erzofri Extended-Release |
| Bausch Health US, LLC | $265.16 | 2021-2025 | Aplenzin, Wellbutrin |
| Tris Pharma INC | $256.75 | 2023-2024 | Dyanavel Xr, Quillichew Er, Quillivant |
| Merck Sharp & Dohme LLC | $191.48 | 2020-2025 | Pifeltro, Delstrigo, Dificid |
| Orexo US, INC. | $189.65 | 2019-2021 | |
| Eisai INC. | $178.00 | 2020-2021 | |
| Braeburn INC. | $177.87 | 2024 | Brixadi |
| Neuronetics, INC. | $175.67 | 2020-2023 | Neurostar Tms Therapy System |
| Emd Serono, INC. | $153.98 | 2023-2025 | Serostim |
| Janssen Biotech, INC. | $143.26 | 2019-2023 | Symtuza |
| Napo Pharmaceuticals INC | $106.34 | 2024-2025 | Mytesi |
| Amgen INC. | $93.19 | 2023-2024 | Otezla, Repatha |
| Adlon Therapeutics L.P. | $70.84 | 2020-2021 | |
| Alfasigma USA, INC. | $67.30 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $52.21 | 2022 | |
| Jazz Pharmaceuticals INC. | $37.64 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.10 | 2024 | Tradjenta, Jardiance, Synjardy |
| Grifols USA, LLC | $27.83 | 2024 | Xembify |
| Scilex Pharmaceuticals INC. | $24.82 | 2020 | |
| Redhill Biopharma INC. | $24.81 | 2021 | |
| Valinor Pharma, LLC | $22.73 | 2023 | Movantik |
| Noven Therapeutics, LLC | $21.53 | 2021 | |
| Acerus Pharmaceuticals Corporation | $21.03 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $21.02 | 2023 | Farxiga |
| Mdd US Operations, LLC | $19.80 | 2019 | |
| Novo Nordisk INC | $18.10 | 2021 | |
| Sumitomo Pharma America, INC. | $17.98 | 2025 | Gemtesa |
| Biodelivery Sciences International, INC. | $16.44 | 2020 | |
| Lilly USA, LLC | $16.12 | 2020 | |
| Vertical Pharmaceuticals, LLC | $15.94 | 2019 | |
| Uswm, LLC | $15.55 | 2022 | |
| Antares Pharma, INC. | $14.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.